Mobile

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not a...

Mise à jour : Il y a 4 ans
Référence : ISRCTN10059974

A randomised phase II study of cytotoxic chemotherapy or cytotoxic chemotherapy combined with celecoxib or trastuzumab as primary chemotherapy for patients with high risk localised breast cancer not amenable to breast conserving therapy

Femme Homme

  • | Pays :
  • France
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Not provided at time of registration

Critère d'inclusion

  • Localised breast cancer not amenable to breast conserving therapy

Liens